Response to “Germ Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman [Book Review]

Cambridge Quarterly of Healthcare Ethics 8 (1):88-96 (1999)
  Copy   BIBTEX

Abstract

Germ-line therapy has long been regarded with great caution both by scientists and by ethicists. Even those who do not reject germ-line therapy in principle have tended to reject it in practice as carrying unacceptable risks in our current state of knowledge. For this reason, a recent paper by Rubenstein, Thomasma, Shon, and Zinaman is unusual in putting forward a serious proposal for the use of germ-line therapy in the foreseeable future

Categories

Keywords

Reprint years

DOI

10.1017/s0963180199001140

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,069

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Responses and Dialogue: Response to “Germ-Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman. [REVIEW]Matthew D. Bacchetta & Gerd Richter - 1996 - Cambridge Quarterly of Healthcare Ethics 5 (3):450.
Responses and Dialogue: Response to “Germ-Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3.). [REVIEW]Matthew D. Bacchetta & Gerd Richter - 1996 - Cambridge Quarterly of Healthcare Ethics 5 (3):450-457.
Response to “Germ Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3). [REVIEW]Imre Szebik - 1999 - Cambridge Quarterly of Healthcare Ethics 8 (3):369-374.
Response to “Germ Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3) Altering the Mitochondrial Genome: Is it Just a Technical Issue? [REVIEW]Imre Szebik - 1999 - Cambridge Quarterly of Healthcare Ethics 8 (3):369-374.
Germ-Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation.Donald S. Rubenstein, David C. Thomasma, Eric A. Schon & Michael J. Zinaman - 1995 - Cambridge Quarterly of Healthcare Ethics 4 (3):316.
Germ-line therapy for mitochondrial disease: some ethical objections.Helen Watt - 1999 - Cambridge Quarterly of Healthcare Ethics 8 (1):88.
Ethical questions in human germ-line gene therapy.Imre Szebik - unknown
Response to “Dimensions and Classification of Genetic Interventions in the Human Genome” by Matthew D. Bacchetta and Gerd Richter - Misinterpretations and Misrepresentations.Donald S. Rubenstein - 1998 - Cambridge Quarterly of Healthcare Ethics 7 (1):90-93.
Is Mitochondrial Donation Germ‐Line Gene Therapy? Classifications and Ethical Implications.Anthony Wrigley & Ainsley J. Newson - 2016 - Bioethics 31 (1):55-67.
Commentary: How do we think about the ethics of human germ-line genetic therapy?Kathleen Nolan - 1991 - Journal of Medicine and Philosophy 16 (6):613-619.

Analytics

Added to PP
2010-08-24

Downloads
63 (#262,902)

6 months
11 (#271,985)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Helen Watt
University of Edinburgh (PhD)

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references